瑞思迈财报强劲股价却跌，市场担忧竞争与成本压力

Core Viewpoint - ResMed's stock price declined by 2.82% despite strong quarterly earnings, primarily due to concerns over long-term competitive risks overshadowing short-term positive results [1][5] Financial Performance - For Q2 of FY2026, ResMed reported a revenue increase of 11% year-over-year to $1.423 billion, with a non-GAAP EPS of $2.81, exceeding market expectations [1] - Gross margin improved to 61.8%, reflecting cost optimization and operational efficiency [1] - Sales and administrative expenses rose by 15%, outpacing revenue growth, driven by increased employee costs and marketing investments [3] - The effective tax rate increased from 18% to 21.1%, which somewhat constrained net profit growth [3] Recent Company Developments - Market focus has shifted to the potential impact of new therapies on ResMed's traditional device business, particularly with Apnimed's oral sleep apnea drug AD109 showing a 47% efficacy in Phase 3 trials [2] - If approved by the FDA and launched in 2027, this drug could disrupt ResMed's device-centric business model [2] - Management did not directly address this competitive threat during the earnings call, leading to investor concerns about the drug replacement trend affecting long-term growth expectations [2] Industry Environment - Competitors like Philips are gradually re-entering the U.S. market, which may intensify industry competition [4] - The rise of GLP-1 drugs is viewed by some institutions as potentially increasing the diagnosis rate of sleep apnea, but there are concerns that it may lead to a reduction in device usage among some patients [4] Institutional Perspectives - Following the earnings report, several institutions updated their ratings: Canaccord Genuity raised the target price to $314, while Morgan Stanley maintained a "Buy" rating [5] - However, Needham and other institutions expressed caution, reflecting a divergence in market sentiment regarding competitive dynamics [5]